ADIPOQ and metabolic dysfunction-associated steatotic liver disease: The study by John et al. (49) newly indicated that recipient adiponectin (ADIPOQ) rs1501299 and rs17300539 polymorphisms are associated with de novo NAFLD among patients transplanted for hepatitis C. De novo diabetes mellitus, as risk factor for post-LT NAFLD was associated with the following SNPs: recipient angiotensinogen (AGT) rs699; recipient mTOR rs2295080 (only following everolimus use); recipient ADIPOQ rs1501299 and rs822396; donor and recipient small ubiquitin like modifier 4 (SUMO4) rs237025 (50).